ETNB 89BIO INC revenue, earnings and financials
For the quarter ended June 30, 2025, 89BIO INC reported revenue of n/a, net income of −$112M and diluted EPS of −$0.71; for the fiscal year ended December 2024 revenue was n/a.
ETNB annual revenue and earnings
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$385M, net income −$367M (margin n/a), EPS −$3.51
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$151M, net income −$142M (margin n/a), EPS −$2.00
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$102M, net income −$102M (margin n/a), EPS −$2.93
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$89.7M, net income −$90.1M (margin n/a), EPS −$4.48
ETNB quarterly revenue and earnings
- Quarter ended Jun 30, 2025: revenue n/a, net income −$112M, EPS −$0.71
- Quarter ended Mar 31, 2025: revenue n/a, net income −$71.3M, EPS −$0.49
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$118M, EPS −$1.10
- Quarter ended Sep 30, 2024: revenue n/a, net income −$149M, EPS −$1.39
- Quarter ended Jun 30, 2024: revenue n/a, net income −$48.0M, EPS −$0.48
- Quarter ended Mar 31, 2024: revenue n/a, net income −$51.7M, EPS −$0.54
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$40.2M, EPS −$0.49
- Quarter ended Sep 30, 2023: revenue n/a, net income −$34.7M, EPS −$0.45
- Quarter ended Jun 30, 2023: revenue n/a, net income −$38.4M, EPS −$0.52
- Quarter ended Mar 31, 2023: revenue n/a, net income −$28.8M, EPS −$0.54
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$24.6M, EPS $0.13
- Quarter ended Sep 30, 2022: revenue n/a, net income −$26.8M, EPS −$0.57
- Quarter ended Jun 30, 2022: revenue n/a, net income −$25.1M, EPS −$1.23
- Quarter ended Mar 31, 2022: revenue n/a, net income −$25.6M, EPS −$1.26
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$26.3M, EPS −$1.30
- Quarter ended Sep 30, 2021: revenue n/a, net income −$28.3M, EPS −$1.41
- Quarter ended Jun 30, 2021: revenue n/a, net income −$20.7M, EPS −$1.03
- Quarter ended Mar 31, 2021: revenue n/a, net income −$14.8M, EPS −$0.74
ETNB cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$368M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$129M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$81.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$76.8M, share buybacks n/a
ETNB balance sheet
- Jun 30, 2025: cash $129M, total assets $603M, total liabilities $81.8M, shareholders' equity $522M, long-term debt $36.2M
- Mar 31, 2025: cash $315M, total assets $685M, total liabilities $79.6M, shareholders' equity $605M, long-term debt $35.9M
- Dec 31, 2024: cash $126M, total assets $479M, total liabilities $77.9M, shareholders' equity $401M, long-term debt $35.7M
- Sep 30, 2024: cash $91.4M, total assets $458M, total liabilities $80.2M, shareholders' equity $378M, long-term debt $35.5M
- Jun 30, 2024: cash $212M, total assets $582M, total liabilities $67.2M, shareholders' equity $515M, long-term debt $20.4M
- Mar 31, 2024: cash $218M, total assets $577M, total liabilities $66.8M, shareholders' equity $511M, long-term debt $23.1M
- Dec 31, 2023: cash $316M, total assets $596M, total liabilities $60.0M, shareholders' equity $536M, long-term debt $24.8M
- Sep 30, 2023: cash $252M, total assets $460M, total liabilities $49.9M, shareholders' equity $410M, long-term debt $24.6M
Is ETNB profitable?
No. 89BIO INC lost $450M over the last four quarters.
What is ETNB's EPS?
Diluted earnings per share over the last four quarters were −$3.69; −$0.71 in the latest quarter.